Welcome to our dedicated page for ACLARION news (Ticker: ACONW), a resource for investors and traders seeking the latest updates and insights on ACLARION stock.
Aclarion Inc (ACONW) delivers innovative healthcare solutions through its Nociscan platform, combining MR spectroscopy and AI-driven diagnostics to address chronic low back pain. This page serves as the definitive source for official company announcements and medically validated progress updates.
Access timely updates on clinical trial results, strategic partnerships, and technological enhancements directly from the source. Investors and medical professionals will find curated information spanning product developments, research collaborations, and business milestones – all essential for understanding the company's position in medical diagnostics.
Our repository includes verified reports on biomarker validation studies, SaaS platform updates, and healthcare provider adoption metrics. Bookmark this page to efficiently track Aclarion's progress in transforming spine care through noninvasive diagnostic innovation.
Aclarion, a healthcare technology company focused on chronic low back pain, announced significant findings from a clinical trial involving 78 patients. The trial demonstrated an 85% success rate for surgeries targeting discs identified by Nociscan, marking a 22 percentage point improvement over treatments not aligned with Nociscan results (85% vs. 63%; p=0.07). Nociscan, an augmented intelligence platform, measures pain biomarkers without invasive procedures like discography. This two-year durability data, published in the European Spine Journal, emphasizes the platform's potential to aid physicians in optimizing treatment strategies. Aclarion plans to continue clinical trials to further validate these findings and present additional economic benefits at upcoming conferences.
FAQ
What is the current stock price of ACLARION (ACONW)?
